However, recent studies turned the spotlight on the inflammation, as shown in the CANTOS trial, in which Canakinumab, a human monoclonal antibody targeting IL-1β, reduced the total CV burden expressed as nonfatal myocardial infarction, stroke, or cardiovascular death [53]. The gene discussed is IL1B; the disease is stroke disorder.